

Discussions with leaders: Czernin and Herrmann interview Rodney Hicks about his 3 decades of practice, research, and clinical trial achievements in advancing nuclear medicine in Australia. **Page 1**

α -emitter labeling review: Yang and colleagues provide a state-of-the-art overview of methods for incorporation of α -emitting isotopes into radiopharmaceuticals, with a focus on new discoveries and remaining challenges. **Page 5**

Imaging ICI-induced myocarditis: Rischpler and colleagues look at the potential for nuclear medicine imaging techniques in detecting early immune-related adverse events after immune checkpoint inhibitor therapy. **Page 14**

Molecular breast imaging: Covington and colleagues highlight current instrumentation, indications, and clinical applications for breast-specific γ imaging and describe likely future innovations. **Page 17**

AR imaging with ^{18}F -FDHT PET: Jacene and colleagues explore imaging of androgen receptors with ^{18}F -fluoro-5 α -dihydrotestosterone PET in patients with estrogen receptor-positive metastatic breast cancer receiving selective androgen receptor modulation therapy. **Page 22**

Assessing CLI: olde Heuvel and colleagues evaluate the accuracy of Cerenkov luminescence imaging after ^{68}Ga -prostate-specific membrane antigen injection in intraoperative margin assessment during prostatectomy and investigate the characteristics of the resulting chemiluminescence signal. **Page 29**

First-in-human ^{11}C -glutamine PET: Cohen and colleagues report on the radiologic safety and biodistribution of this tracer designed to study glutamine uptake and metabolism with PET in a group of patients with confirmed metastatic colorectal cancer. **Page 36**

Targeting PARP-1 in ovarian cancer: Young and colleagues characterize the pharmacokinetics of ^{18}F -fluorothantrate and test kinetic and static models to guide metric selection in future studies of this tracer as a biomarker of response to poly-(adenosine diphosphate-ribose) polymerase-inhibitor therapy. **Page 44**

c-MET fluorescence penile cancer imaging: de Vries and colleagues present the first results of a prospective feasibility study for real-time

intraoperative visualization of penile squamous cell carcinoma using a fluorescent mesenchymal-epithelial transition factor receptor-targeting tracer. **Page 51**

^{90}Y versus systemic therapy: Salem and Gabr offer perspective on current clinical practice and national trends in transarterial radioembolization and systemic therapy for hepatocellular carcinoma. **Page 57**

AUC for PSMA PET: Jadvar and a multidisciplinary working group provide detailed appropriate use criteria and decision-making scenarios for prostate-specific membrane antigen PET imaging in prostate cancer. **Page 59**

Dual-tracer PET/CT in CRPC: Chen and colleagues determine the added value of ^{18}F -FDG PET/CT imaging to that of ^{68}Ga -prostate-specific membrane antigen PET/CT in patients with castration-resistant prostate cancer and identify patients who may benefit from dual-tracer imaging. **Page 69**

EAU risk groups and PSMA PET stage: Ferdinandus and colleagues look at rates of local and metastatic disease on prostate-specific membrane antigen PET in biochemical recurrence and persistence of prostate cancer as stratified by European Association of Urology risk guidelines. **Page 76**

^{68}Ga -FAPI PET/MR in gastric cancer: Qin and colleagues describe the performance of ^{68}Ga -DOTA-FAPI-04 PET/MR for diagnosis of primary tumor and metastatic lesions in patients with gastric carcinomas and compare results with those from ^{18}F -FDG PET/CT. **Page 81**

^{68}Ga -FAPI PET in sarcoma: Kessler and colleagues report on the endpoints of a ^{68}Ga -FAPI PET prospective observational trial in patients with bone or soft-tissue sarcomas, including histopathologic comparisons and validation of diagnostic imaging. **Page 89**

CXCR4 imaging in MPN: Kraus and colleagues detail the feasibility of C-X-C motif chemokine receptor 4-directed imaging with PET/CT using ^{68}Ga -pentixafor to visualize and quantify disease involvement in patients with myeloproliferative neoplasms. **Page 96**

Dose-response and peptide-receptor radionuclide therapy: Tamborino and colleagues build a refined dosimetry model for ^{177}Lu -DOTATATE preclinical experiments enabling correlation of absorbed dose with

double-strand break induction and cell death. **Page 100**

^{18}F -Flortaucipir and ^{18}F -MK-6240 PET: Gogola and colleagues directly compare brain distribution, specific signal, and off-target binding of these 2 frequently used PET tau tracers in elderly individuals with varying clinical diagnoses and cognition. **Page 108**

β -Amyloid PET signal source: Biechele and colleagues report on 2 murine cerebral amyloidosis models that present with distinct β -amyloid plaque compositions and explore the respective biochemical contributions to A β PET signal in vivo. **Page 117**

^{68}Ga -FAPI-04 PET/CT for fibrosis imaging: Schmidkonz offers perspective on fibroblast activation protein-specific PET/CT in fibrotic interstitial lung diseases and previews a related article in this issue of *JNM*. **Page 125**

^{68}Ga -FAPI PET/CT in FILD and LC: Röhrich and colleagues evaluate the imaging properties of static and dynamic fibroblast activation protein inhibitor PET/CT in various types of fibrotic interstitial lung disease, including preclinical assessments and studies in human biopsy samples. **Page 127**

Post-COVID-19 vaccine PET/CT: Eifer and colleagues detail PET/CT uptake in the deltoid muscle and axillary lymph nodes of patients who received a COVID-19 mRNA-based vaccine and evaluate its association with patient age and immune status. **Page 134**

^{18}F -FAraG imaging of CNS T cells: Guglielmetti and colleagues explore the potential of 2'-deoxy-2'- ^{18}F -fluoro-9- β -D-arabinofuranosylguanine PET imaging to assess infiltrating T cells in multiple sclerosis and to provide, in combination with MRI, a novel tool to determine lesion types. **Page 140**

^{18}F -FDOPA radiomics in gliomas: Zaragori and colleagues determine whether a range of ^{18}F -FDOPA PET radiomics feature sets improve ^{18}F -FDOPA PET imaging performance as an adjunct to MRI and describe the contributions of each of the features. **Page 147**

AI for coronary PET and CT angiography: Kwiecinski and colleagues combine coronary ^{18}F -sodium fluoride PET and CT angiography-based quantitative plaque analysis to develop an optimal machine-learning model for risk prediction of myocardial infarction in patients with stable coronary disease. **Page 158**